Sandu Pharma board approves unaudited financial results for Q2FY27 and half year ended September 30
BSE India
Sandu Pharma board approves the unaudited financial results for the quarter and half year ended September 30, 2026. The results comply with Ind-AS and include a Limited Review Report from Dave & Dave Chartered Accountants. The company makes these audited figures available on its official website for shareholder review.
| Sep 2026 | Jun 2026 | Sep 2025 | QoQ% | YoY% | |
|---|---|---|---|---|---|
| Revenue/Sales | 19.43 | 16.39 | 17.62 | 18.55% | 10.26% |
| EBITDA | 1.05 | 0.55 | 0.91 | 89.60% | 15.46% |
| Op. profit margin(%) | 4.96 | 3.27 | 4.89 | 51.43% | 1.38% |
| Net Profit | 0.79 | 0.23 | 0.52 | 244.08% | 49.76% |
| EPS | 0.68 | 0.37 | 0.54 | 83.78% | 25.93% |
* Standalone data
